- Home
- / Kyung Nam Pharm
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Kyung Nam Pharm financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Revenue
₩60.8 B
FY, 2024
CreditSafe Score
?
Score changed on Jun 09, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| KRW | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2023 | FY, 2024 |
|---|---|---|---|---|---|---|---|
| Revenue | 41.4B | 44.8B | 70.9B | 64.6B | 59.0B | 68.4B | 60.8B |
| Cost of goods sold | 18.5B | 21.4B | 35.4B | 35.3B | 16.8B | 46.1B | 41.7B |
| Gross profit | 33.5B | 23.6B | 37.0B | 31.6B | 42.7B | 23.2B | 19.7B |
| Gross profit margin, % | 80.7% | 52.6% | 52.2% | 48.9% | 72.4% | 33.8% | 32.4% |
| Operating expense total | 23.1B | 25.4B | 31.8B | 35.2B | 26.1B | 26.3B | 17.5B |
| Depreciation and amortization | 2.1B | 2.9B | 1.6B | 1.8B | 4.3B | 3.1B | 2.5B |
| EBITDA | 10.4B | (1.8B) | 5.2B | (3.7B) | 16.6B | (3.4B) | 2.3B |
| EBITDA margin, % | 25.0% | -4.1% | 7.4% | -5.7% | 28.2% | -4.9% | 3.7% |
| EBIT | 7.6B | (5.1B) | 2.9B | (7.2B) | 11.8B | (20.1B) | (2.2B) |
| EBIT margin, % | 18.3% | -11.5% | 4.1% | -11.1% | 20.0% | -29.3% | -3.6% |
| Interest income | 115.3M | 280.6M | 170.2M | 86.4M | 529.7M | 738.0M | 1.1B |
| Interest expense | 1.3B | 323.4M | 1.2B | 1.6B | 19.5B | 2.7B | 2.0B |
| Pre tax profit | 6.3B | (6.2B) | (7.5B) | (3.3B) | (7.4B) | (21.1B) | (3.2B) |
| Income tax expense | 2.6B | (1.7B) | (2.0B) | (90.4M) | (615.2M) | 1.2B | 862.7M |
| Net Income | 3.7B | (4.5B) | (5.5B) | (3.2B) | (6.8B) | (22.2B) | (4.1B) |